Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell–Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy

• Four B cell–depleted non-Hodgkin lymphoma (NHL) patients with SARS-CoV-2 pneumonia after rituximab therapy were initially treated with a 5-day remdesivir course and steroids. After transient virologic and clinical response, they all experienced early relapse and subsequent prolonged disease course...

Descripción completa

Detalles Bibliográficos
Autores principales: Furlan, Anna, Forner, Gabriella, Cipriani, Ludovica, Vian, Elisa, Rigoli, Roberto, Gherlinzoni, Filippo, Scotton, Piergiorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139434/
https://www.ncbi.nlm.nih.gov/pubmed/34217677
http://dx.doi.org/10.1016/j.clml.2021.05.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139434/
https://www.ncbi.nlm.nih.gov/pubmed/34217677
http://dx.doi.org/10.1016/j.clml.2021.05.013

Ejemplares similares